Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Castle Biosciences’s reported figures.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
FAQ
- What is Castle Biosciences's EBIT?
- Castle Biosciences (CSTL) reported EBIT of -$18.41M in Q1 2026.
- How has Castle Biosciences's EBIT changed year-over-year?
- Castle Biosciences's EBIT increased by 34.1% year-over-year, from -$27.93M to -$18.41M.
- What is the long-term trend for Castle Biosciences's EBIT?
- Over 4 years (2021 to 2025), Castle Biosciences's EBIT has grown at a 1.7% compound annual growth rate (CAGR), from -$40.08M to -$42.81M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Castle Biosciences's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude